Lurbinah Week 4

Lizzy Urbina

Template:lurbinah

Assignments

• BIOL368/S20:Week 1
• BIOL368/S20:Week 2
• BIOL368/S20:Week 3
• BIOL368/S20:Week 4
• BIOL368/S20:Week 5
• BIOL368/S20:Week 6
• BIOL368/S20:Week 8
• BIOL368/S20:Week 9
• BIOL368/S20:Week 10
• BIOL368/S20:Week 13
• BIOL368/S20:Week 14

Weekly Assigments

• lurbinah Week 2
• lurbinah Week 3
• lurbinah Week 4
• lurbinah Week 5
• lurbinah Week 6
• lurbinah Week 7
• lurbinah Week 8
• lurbinah Week 9
• lurbinah Week 10
• lurbinah Week 11
• lurbinah Week 12
• lurbinah Week 13
• lurbinah Week 14

Class Journal Assigments

• BIOL368/S20:Class Journal Week 1
• BIOL368/S20:Class Journal Week 2
• BIOL368/S20:Class Journal Week 3
• BIOL368/S20:Class Journal Week 4
• BIOL368/S20:Class Journal Week 5
• BIOL368/S20:Class Journal Week 6
• BIOL368/S20:Class Journal Week 7
• BIOL368/S20:Class Journal Week 8
• BIOL368/S20:Class Journal Week 9
• BIOL368/S20:Class Journal Week 10
• BIOL368/S20:Class Journal Week 11
• BIOL368/S20:Class Journal Week 12
• BIOL368/S20:Class Journal Week 13
• BIOL368/S20:Class Journal Week 14

Myth 7

1. myth is that treatment equity does not match to the pharmaceutical industry power and profits
2. the primary objective should not be to attack the industry, instead, look for answers in how those at higher risk could be prevented from getting infected? and how anyone regardless of income can have access to medicine?
3. There are two types of drug companies, research-based, and generic firms.
4. Industry spends more money on advertising than on actual research
5. IP rights purpose is to protect the interest of the inventors and give some type of reward to original research
6. Low- and middle-income countries should take advantage of any mechanisms that will allow them to provide treatment at the lowest cost
7. Wealthy countries and donors should found the GFATM, which will benefit research-based companies and generic firms.
8. the possibility of bulk purchase of treatment from the GFATM should be studied, to provided high-quality treatment to the poor.
9. Public-Private partnership initiative should be proposed and supported
10. Activist's objective should be to find the answers of the first two questions, through strategies that create outside forces that will pressure the drug companies to value justice and compassion.

Myth 8

• Myth: The budget in poor countries should be allocated to bigger issues that affect many, instead of expensive treatment that will benefit only a few.
• Response: the high cost of ARV treatments in poor countries does not only benefit a few, instead it is part of the strategy to control the damage caused by AIDs in health. security and stability of society.
• Considerations that must be taken when evaluating the role of ARV treatment in poor countries which showed the impact of a wide segment of the population reinforcing countries' health agendas.
  • the distribution of Aids among the population and its impact on life expectancy.
  • the consequences AIDs have on food production and nutrition.
  • the relationship between AIDS and other infectious diseases
  • the AIDS orphan crisis
  • The impact of HIV/AIDS on the health care systems in poor countries.
• Treating AIDS should be a public health priority
  • AIDS kills predominately young adults
  • Decline in life expectancy
• Treating AIDS should be an economic priority
  • If life expectancy declines, so does its country's capacity to make money
• Agriculture production is being affected by AIDS
  • According to FAO 7million workers have died of AIDS-related causes and 16 million more are expected to die in the next 20 years.
  • this disrupts the transmission of agricultural knowledge and land management through generations.
• ARV treatment should be part of the response to the economic, and agricultural crisis
• HIV positive increases the risk
• Children whose parents are sick are more likely to get sick from other preventable diseases.
• AIDS rapidly increases the number of orphans, exposing them to economic, social, health, and educational struggles.